Scientists at the University of Oxford demonstrate an approach to interpreting how materials interact with polarized light, ...

Non-terrestrial networks, combined with early 6G research, demand test equipment capable of handling extreme parameters and ...

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...

Phase 1a/1b study in 97 patients demonstrates mitochondrial metabolic reprogramming induced by BPM31510-IV and supports advancement in multiple ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

Formation Bio and Lynk Pharmaceuticals today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant ...

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

Elliptical retarder model improves polarization analysis for material design and biomedical imaging. The work, reported in Advanced Photonics Nexus, focuses on improving how researchers analyze a key ...

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006 from Lynk Pharmaceuticals.

LNK01006 recently received IND clearance from the FDA to initiate first-in-human studies in the US. Formation Bio plans to initiate a Phase 1 study in the first half of 2026, reflecting the company's ...